Skip to search formSkip to main contentSkip to account menu

volociximab

Known as: anti-![GREEK SMALL LETTER ALPHA]!5![GREEK SMALL LETTER BETA]!1 integrin MOAB, anti-alpha 5 beta 1 integrin monoclonal antibody, anti-?5?1 integrin 
A monoclonal antibody that is being studied in the treatment of some types of cancer. Monoclonal antibodies are made in the laboratory and can locate… 
National Institutes of Health

Related topics

Related topics

5 relations

Narrower (1)

M200

Broader (1)

Monoclonal Antibodies
NCIt Antineoplastic Agent Terminologyantigen bindingdacarbazine/volociximab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Volociximab in cancer
Introduction: Volociximab is a first-in-class chimeric monoclonal antibody that targets α5β1 integrin. Preclinical studies have… 
Highly Cited
2011
Highly Cited
2011
A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer.
Highly Cited
2008
Highly Cited
2008
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
Highly Cited
2008
Highly Cited
2008
Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study
Purpose: This study aimed to assess the safety and feasibility of administering volociximab, a chimeric monoclonal antibody that… 
Highly Cited
2008
Highly Cited
2008
Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits
SummaryAngiogenesis, the process by which new blood vessels form from existing vasculature, is critical for tumor growth and… 
2008
2008
Results from a phase 1/2 study of volociximab in combination with liposomal doxorubicin in relapsed advanced epithelial ovarian and primary peritoneal carcinoma
16527 Background: Preclinical studies demonstrate that the chimeric α5β1 integrin antibody volociximab inhibits tumor… 
Review
2007
Review
2007
Integrin signaling in epithelial cells.
Highly Cited
2007
Highly Cited
2007
Drug evaluation: Volociximab, an angiogenesis-inhibiting chimeric monoclonal antibody.
  • S. Kuwada
  • Current opinion in molecular therapeutics (Print)
  • 2007
  • Corpus ID: 34780594
PDL Biopharma Inc (formerly Eos Biotechnology Inc) and Biogen Idec Inc are developing volociximab, an angiogenesis-inhibiting… 
Highly Cited
2007
Highly Cited
2007
A function blocking anti-mouse integrin α5β1 antibody inhibits angiogenesis and impedes tumor growth in vivo
BackgroundIntegrins are important adhesion molecules that regulate tumor and endothelial cell survival, proliferation and… 
Review
2006
Review
2006
Phase II study of volociximab (M200), an α5β1 anti-integrin antibody in refractory metastatic clear cell renal cell cancer (RCC).
4535 Background: Blocking angiogenesis has been shown to be an effective strategy for controlling tumor growth in RCC. Tumor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)